Last Updated : April 30, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | ||
| Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | List with criteria/condition | Complete | ||
| Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | Do not list | Complete | ||
| Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erleada | Apalutamide | metastatic castration-sensitive prostate cancer (mCSPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erivedge | Vismodegib | Basal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erelzi | Etanercept | Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erbitux | Cetuximab | Cancelled | ||||
| Erbitux | Cetuximab | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active |
Last Updated : April 30, 2024